Author details

Full Name

Marjorie Romkes

Affiliation

ORCID

Career Start Year

1984

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
30824778	PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy.	Sci Rep	2019
26678909	Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.	Neoplasia	2015
25713168	15q12 variants, sputum gene promoter hypermethylation, and lung cancer risk: a GWAS in smokers.	J Natl Cancer Inst	2015
25511740	Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma.	Cancer Lett	2015
26052356	MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603.	Clin Epigenetics	2015
26352532	Lung Cancer Risk Prediction Using Common SNPs Located in GWAS-Identified Susceptibility Regions.	Journal of Thoracic Oncology	2015
25250855	Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer.	American Journal of Respiratory and Critical Care Medicine	2014
24623222	Genotyping technologies: application to biotransformation enzyme genetic polymorphism screening.	Methods in Molecular Biology	2014
24623221	Strategies for measurement of biotransformation enzyme gene expression.	Methods in Molecular Biology	2014
25122423	Inherited variation in the ATP-binding cassette transporter ABCB1 and survival after chemotherapy for stage III-IV lung cancer.	Journal of Thoracic Oncology	2014
23695963	Pathologic and gene expression features of metastatic melanomas to the brain.	Cancer	2013
22926004	Pharmacologic evidence to support clinical decision making for peripartum methadone treatment.	Psychopharmacology	2013
24303297	An empirical workflow for genome-wide single nucleotide polymorphism-based predictive modeling.		2013
23528144	CYP2A6 genotype and smoking behavior in current smokers screened for lung cancer.	Substance Use and Misuse	2013
23523331	Polymorphisms in NAT2 and GSTP1 are associated with survival in oral and oropharyngeal cancer.	Cancer Epidemiol	2013
23619167	Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.	Cancer Discov	2013
23619143	Childhood passive smoke exposure is associated with adult head and neck cancer.	Cancer Epidemiol	2013
23619141	Genetic variation in ESR2 and estrogen receptor-beta expression in lung tumors.	Cancer Epidemiology	2013
23211525	Regulation of the human hydroxysteroid sulfotransferase (SULT2A1) by RORÎ± and RORÎ³ and its potential relevance to human liver diseases.	Mol Endocrinol	2013
21976407	Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer.	Molecular Carcinogenesis	2012
21737503	XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.	Clin Cancer Res	2011
21483023	Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.	J Natl Cancer Inst	2011
21343546	Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.	Journal of Clinical Oncology	2011
21335511	A sex-specific association between a 15q25 variant and upper aerodigestive tract cancers.	Cancer Epidemiol Biomarkers Prev	2011
21363880	Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.	Ann Oncol	2011
21890746	Effects of ERCC2 Lys751Gln (A35931C) and CCND1 (G870A) polymorphism on outcome of advanced-stage squamous cell carcinoma of the head and neck are treatment dependent.	Cancer Epidemiol Biomarkers Prev	2011
21798893	The mutational landscape of head and neck squamous cell carcinoma.	Science	2011
20514470	Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk.	Oncology Reports	2010
19933807	Voriconazole pharmacokinetics in liver transplant recipients.	Antimicrob Agents Chemother	2010
18563706	The impact of genetic variation in DRD2 and SLC6A3 on smoking cessation in a cohort of participants 1 year after enrollment in a lung cancer screening study.	American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics	2009
19381959	Pharmacogenomics.	Methods in Molecular Biology	2009
19959699	Smoking behavior 1 year after computed tomography screening for lung cancer: Effect of physician referral for abnormal CT findings.	Cancer Epidemiology Biomarkers and Prevention	2009
20443940	Team building: electronic management-clinical translational research (eM-CTR) systems.	Clinical and Translational Science	2009
18642288	Case-control study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes.	Head and Neck	2008
18197300	Exogenous and endogenous determinants of blood trihalomethane levels after showering.	Environmental Health Perspectives	2008
18094222	Pharmacokinetics and metabolism of all-trans- and 13-cis-retinoic acid in pulmonary emphysema patients.	J Clin Pharmacol	2008
17054666	Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.	British Journal of Clinical Pharmacology	2007
17219440	Association of the EGFR intron 1 CA repeat length with lung cancer risk.	Mol Carcinog	2007
17492757	Loss of distal 11q is associated with DNA repair deficiency and reduced sensitivity to ionizing radiation in head and neck squamous cell carcinoma.	Genes Chromosomes Cancer	2007
16642541	CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly.	International Journal of Geriatric Psychiatry	2006
17409930	Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.	J Thorac Oncol	2006
16865671	Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never-smokers.	Molecular Carcinogenesis	2006
16952492	Validation of incorporating flurbiprofen into the Pittsburgh cocktail.	Clinical Pharmacology and Therapeutics	2006
17000715	Meta- and pooled analysis of GSTT1 and lung cancer: a HuGE-GSEC review.	Am J Epidemiol	2006
16995867	Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus.	British Journal of Clinical Pharmacology	2006
16424825	The absence of interaction between drug metabolizing enzyme genotypes and maternal lifestyle factors on glycophorin A somatic mutation frequency levels in newborns.	Pharmacogenetics and Genomics	2006
16009381	Metabolic gene polymorphisms and lung cancer risk in non-smokers. An update of the GSEC study.	Mutat Res	2005
15502238	Genotyping technologies: application to biotransformation enzyme genetic polymorphism screening.	Methods in Molecular Biology	2005
15502237	Strategies for measurement of biotransformation enzyme gene expression.	Methods in Molecular Biology	2005
15754315	Association of polymorphisms in the cyclin D1 and XPD genes and susceptibility to cancers of the upper aero-digestive tract.	Mol Carcinog	2005